Agranulocytosis caused by ticlopidine and its mechanism

Am J Hematol. 1991 Aug;37(4):239-42. doi: 10.1002/ajh.2830370405.

Abstract

A 75-year-old female patient with agranulocytosis caused by ticlopidine is reported. She took the drug at 200 mg/day for 30 days to prevent recurrence of cerebral infarction. The leukocyte count at the nadir was 500/microliters on the 34th day since she started to take the drug. Complete recovery of her peripheral leukocytes came 12 days after its withdrawal. In this patient, mechanisms of ticlopidine-caused agranulocytosis were studied. The lymphocyte stimulation test using ticlopidine was negative. In the culture of marrow cells depleted of lymphocytes, ticlopidine directly inhibited the CFU-C in a dose-dependent manner. Neither the serum on the day of admission nor the T-lymphocytes pre-cultured with ticlopidine had any effect on the CFU-C. The lymphocyte stimulation test is useless in an attempt to find the causal drug in agranulocytosis if it is caused in a directly toxic manner. Agranulocytosis caused by ticlopidine is rare, but careful follow-up is necessary in the case of patients on the drug because there are some whose marrow cells are very sensitive to it.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Agranulocytosis / chemically induced*
  • Bone Marrow / drug effects
  • Bone Marrow Cells
  • Colony-Forming Units Assay
  • Female
  • Humans
  • Lymphocyte Activation
  • T-Lymphocytes / cytology
  • Ticlopidine / adverse effects*

Substances

  • Ticlopidine